Navigation Links
Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
Date:11/9/2010

ogy treatment through 'personalized medicine'," said Juergen Engel, Ph.D., Aeterna Zentaris' President and Chief Executive Officer. "We now look forward to the presentation of Phase 2 results for AEZS-108 in advanced endometrial cancer at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics." Third Quarter 2010 Highlights (All amounts are in U.S. dollars)

  • Perifosine received orphan-drug designation by the United States Food and Drug Administration ("FDA") for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants (July 14, 2010).
  • Dr. Jacek Pinski of the Norris Comprehensive Cancer Center awarded a grant from the National Institutes of Health ("NIH") for a Phase 1/2 study in advanced refractory prostate cancer with AEZS-108 (August 5, 2010).
  • An abstract on SolorelTM, an oral synthetic ghrelin receptor agonist currently in Phase 3 as a diagnostic test for Adult Growth Hormone Deficiency ("AGHD") was presented at the Seventh International Congress of Neuroendocrinology in Rouen, France. The data showed that Solorel's accuracy was at least equivalent to the current tests for AGHD (July 14, 2010).
  • Interim Phase 3 data on Solorel demonstrating the potential to provide a simple, well tolerated and safe oral diagnostic test for AGHD was also presented at the Fifth International Congress of the Growth Hormone Research Society and the Insulin-like Growth Factors Society in New York City (October 5, 2010).
  • "Our financial position continues to be solid with $39.9 million in cash and cash equivalents at quarter-end and a current controlled burn rate of approximately $2 million per month," said Dennis Turpin, Senior Vice President and Chief Financial Officer of Aeterna Zentaris. CONSOLIDATED RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2010Revenues were $5.7 million for the three-month period end
    '/>"/>

    SOURCE AETERNA ZENTARIS INC.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
    2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
    3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
    4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
    5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
    6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
    7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
    8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
    9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
    10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
    11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... July 29, 2015 ... the addition of the "Global Biosimilars Market, ... The Global Biosimilars Market, 2015 - ... rapidly growing biosimilars market. With the blockbuster biologics ... minimize costs, biosimilars are being viewed as viable ...
    (Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
    (Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris ... announced it has selected an optimized Erk inhibitor ... in the development of a new class of ... pathway represents a prime target for therapeutic intervention ... activities and survival benefits for B-Raf and Mek ...
    (Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Costello served ... levee system to protect the Orange County, Texas area from future storm surge ... design team in determining several potential levee alignment alternatives for providing protection, Costello also ...
    Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2
    ... DC The Canadian government reportedly is planning ... regulation requiring companies to detail their use of ... gathered under the requirement will be used to ... help to develop appropriate safety measures to protect ...
    ... Corporation, a,subsidiary of KV Pharmaceutical (NYSE: KVa/KVb), is ... January 26, 2009, a nationwide,voluntary recall of the ... at a wholesale or a retail level as ... under conditions that did not,sufficiently comply with current ...
    ... The Scientific business of Thomson Reuters today announced the ... share of scientific research output continues to shrink while ... retains a healthy footing globally in the relative impact ... Science Watch , Thomson Reuters analyzes 12 year,s worth ...
    Cached Biology Technology:World's first mandatory national nanotech rule pending 2ETHEX Corporation Issues Nationwide Voluntary Recall of Products 2ETHEX Corporation Issues Nationwide Voluntary Recall of Products 3ETHEX Corporation Issues Nationwide Voluntary Recall of Products 4ETHEX Corporation Issues Nationwide Voluntary Recall of Products 5ETHEX Corporation Issues Nationwide Voluntary Recall of Products 6Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters 2
    (Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
    (Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
    (Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
    Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
    ... LEXINGTON, Ky. -- A new study co-authored by the ... vaginal progesterone to women who are at a high ... a premature delivery. The new study, published in ... described a two-prong strategy used by doctors: participating pregnant ...
    ... from Oregon has collected microbes from ice within a lava ... in cold, Mars-like conditions. The microbes tolerate temperatures near ... in the absence of organic food. Under these conditions their ... a common volcanic mineral found in the rocks of the ...
    ... DC -- The American Civil Liberties Union and ... Court to hear Association for Molecular Pathology v. U.S. ... validity of patents on two human genes associated with ... Liberties Union and the Public Patent Foundation originally filed ...
    Cached Biology News:New study shows promise for preventing preterm births 2Scientists find microbes in lava tube living in conditions like those on Mars 2Scientists find microbes in lava tube living in conditions like those on Mars 3U.S. Supreme Court petitioned to review AMP, et al. lawsuit on gene patents 2U.S. Supreme Court petitioned to review AMP, et al. lawsuit on gene patents 3
    Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
    Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
    ...
    ... The E. coli protein sample ... to give a consistent pattern when ... rehydration and sample buffer. This sample ... to validate your 2-D system and ...
    Biology Products: